Seth Lederman

Co-Founder, Chief Executive Officer and Chairman of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP)

[Seth Lederman @SethLederman]

Complex conditions like fibromyalgia don't always follow a linear path, and responsive care can't be built on that premise. Today in @RealClearHealth, I outline how policy and research can accelerate a shift in better treating invisible conditions and chronic illnesses:

https://t.co/SaL9dI3vYO

[Seth Lederman @SethLederman]

For many patients with chronic illnesses, symptoms build over time. But healthcare systems often respond best to acute crises.

In my new op-ed, I explore why persistent symptoms deserve earlier intervention.

Read here: https://t.co/waDNtUMVyO

#Fibromyalgia #ChronicIllness #LymeDisease #Healthcare

[Tonix Pharmaceuticals @TonixPharma]

“Your tests are normal.” Words that people might hear, yet their lives are anything but.

In a new op-ed, Tonix CEO @SethLederman discusses why patient experiences aligned with the latest advances in medicine must remain central to care.

Read more: https://t.co/t8FCIAhNQ0

#Fibromyalgia #ChronicPain #Tonix

[Seth Lederman @SethLederman]

Patients can experience debilitating symptoms even when scans and lab work appear “normal.”

Too many people living with fibromyalgia and other chronic conditions can spend years without answers because their symptoms are difficult to measure.

I wrote about why it's time for patients to have a seat at the table for the care they receive.

https://t.co/jNu8CBBhWN

#Fibromyalgia #ChronicPain #Tonix

[Seth Lederman @SethLederman]

I’m honored to present at the 2nd Richard Slayman Clinical Xenotransplantation Workshop at @nyulangone this Sunday. It’s an important event to discuss innovations, including @TonixPharma’s 3rd-gen, anti-CD40-ligand antibody for the prevention of kidney transplant rejection.

[Tonix Pharmaceuticals @TonixPharma]

On Fibromyalgia Awareness Day, watch a new video episode of The Fibro Show featuring Tonix CEO @SethLederman Lederman in conversation with Sharon Waldrop, host and Fibromyalgia Association founder.

Tonix is dedicated to supporting the fibromyalgia community. Alongside The Fibro Show, we are sponosring the Fibromyalgia Association’s 25th Annual Fibromyalgia Awareness Day.

Register: https://t.co/0KEMopJRBS

#FibromyalgiaAwarenessMonth #FibromyalgiaAwarenessDay #Fibromyalgia

[Seth Lederman @SethLederman]

Cases of Lyme disease are rising. Too many patients are dismissed without answers, and there are still no FDA-approved vaccines or prophylactics to protect against it.

Early recognition and awareness matter.

https://t.co/dIgsq27at6

[Seth Lederman @SethLederman]

Washington is finally asking the right questions about Lyme disease. With 87M Americans at risk & ER visits surging, we need real solutions, not just 'wear long pants.' The answers are closer than ever. My latest on what's coming next.
https://t.co/c1bXc6wWyS

[Seth Lederman @SethLederman]

Lyme disease risk is expanding, and prevention needs to evolve with it.

At Tonix Pharmaceuticals, we are advancing TNX-4800 as an investigational human monoclonal antibody.

Thanks to @DrugDiscovNews and Bree Foster for the conversation.

[Tonix Pharmaceuticals @TonixPharma]

Lyme disease is spreading beyond traditional regions, bringing new urgency to how we think about prevention.

At Tonix, we are advancing TNX-4800 as a differentiated approach.

Thanks to @DrugDiscovNews for the feature and to Bree Foster for the conversation with @SethLederman Lederman.

Read more: https://t.co/O5S9c5sFQB

[Seth Lederman @SethLederman]

RT @TonixPharma: Lyme disease is spreading beyond traditional regions, bringing new urgency to how we think about prevention.

At Tonix, we…

[Seth Lederman @SethLederman]

Chronic pain is a complex condition that requires more than awareness. Expanding access to non-opioid treatment options is important to improve outcomes for patients. Policy initiatives like this represent meaningful progress.

https://t.co/7I3PBSVoFz

[Tonix Pharmaceuticals @TonixPharma]

Check out new coverage from @PharmaVoice on efforts to address #LymeDisease, including Tonix’s investigational #monoclonalantibody, TNX-4800, for prevention in the U.S.

Learn more: https://t.co/4T2lDiiGkG

#InfectiousDisease #Tonix #Biotech

[Tonix Pharmaceuticals @TonixPharma]

Clinical Trials Arena recently highlighted Tonix’s Phase 2 ready investigational human #monoclonalantibody, TNX-4800, for #Lymedisease prevention in the U.S.

Read more: https://t.co/bM3KmjqiWt

#InfectiousDisease #Tonix #Biotech

[Seth Lederman @SethLederman]

Fibromyalgia patients wait many years for a diagnosis. Not because we lack science, but because care hasn’t caught up.

Read more here in my new post: https://t.co/q2NaYEfHZx

#Fibromyalgia #ChronicPain

[Tonix Pharmaceuticals @TonixPharma]

Fibromyalgia affects millions, yet diagnosis is often delayed for years.

In a new post, Tonix CEO @SethLederman, MD, reflects on the scientific innovation and care delivery gap for patients.

https://t.co/efK8qqp8qR

#Fibromyalgia #ChronicPain

[Tonix Pharmaceuticals @TonixPharma]

A recent @nytimes article draws important attention to the long and misunderstood journey of conditions including endometriosis and #fibromyalgia. Fortunately, it seems a broader shift is underway in how #chronicpain is understood.

https://t.co/3B1Y8SbYao

[Seth Lederman @SethLederman]

Interesting perspective in @nytimes: Fibromyalgia took years to be recognized as a serious condition.

Now, we may be seeing a similar shift for endometriosis.
An important moment in how we understand chronic pain.

https://t.co/ZQF7zNncM7

[Seth Lederman @SethLederman]

The suffering described by Virginia Woolf closely resembles what we now recognize as fibromyalgia. Today we understand chronic pain far better, yet patients still spend years searching for answers. In my latest article, I explore how medicine can close that gap.

Read the full piece: https://t.co/lI98RyQRbm

#ChronicPain #Fibromyalgia

[Tonix Pharmaceuticals @TonixPharma]

With ~70 million Americans living, working, or vacationing in tick-endemic zones, Lyme disease is a public health crisis. There’s no FDA-approved vaccine or preventive therapy in the U.S, which Tonix hopes to address with our Phase 2 ready program.
https://t.co/o0pqSHwVGX

[Tonix Pharmaceuticals @TonixPharma]

Mpox is an emerging infectious disease that is now surfacing globally, including NY and the U.S. (with risk remaining low). Tonix is developing an attenuated investigational vaccine with the potential capability to protect against smallpox and mpox. https://t.co/L5CGyENYQl